Form 4: Forte Biosciences CFO Antony A. Riley Reports Stock Transactions
SEC Form 4
Forte Biosciences CFO Antony A. Riley reports the acquisition and disposal of company stock and restricted stock units on April 1, 2024.
Summary
- On April 1, 2024, Antony A. Riley, CFO of Forte Biosciences, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
- Riley acquired 9,375 shares of common stock through the vesting of restricted stock units.
- Concurrently, Riley disposed of 3,345 shares of common stock at a price of $0.7075 per share.
- Following these transactions, Riley directly owns 194,474 shares of Forte Biosciences common stock and 103,125 restricted stock units.
Sentiment
Score: 5
Explanation: This is a standard regulatory filing reflecting routine stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock and RSU transactions |
| 04/02/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.